Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.
Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.
Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.
评论内容